Clinical Trial Update: Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group [Phase 2, Phase 3]

View source ↗

Summary

Completed phase 2/3 trial of Removab (catumaxomab) in EpCAM-positive patients with symptomatic malignant ascites, comparing with an untreated control. Indicatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Malignant Ascites
• Ovarian Cancer

Drugs mentioned

• Removab (catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites | Phase 2, Phase 3 | Status: COMPLETED